- Stéphane Altaba, with extensive experience in biotechnology companies, becomes CEO of LXRepair
- He will lead the commercial launch of Safer Rad-LX®, the first predictive test on toxicity of radiotherapy treatments, and he is expected to raise Series A financing.
Paris, January 20, 2021 – LXRepair, a biotechnology start-up specializing in personalized medicine testing, today announced the appointment of Stéphane Altaba as Chief Executive Officer of LXRepair.
Stéphane Altaba brings over the last 25 years a strong experience in the pharmaceutical and diagnostic industry. His initial mission will be to lead the commercial launch of the first predictive test for the toxicity of radiotherapy treatments, called Safer Rad-LX®, for patients suffering from breast and prostate cancer.
In parallel he will be responsible for raising a Serie A financing round, scheduled for 2021.
“I am delighted that Stéphane has agreed to join us in this essential development phase of the company. His experience in the field of diagnostics and his knowledge of the pharmaceutical industry and oncology will be very valuable to us. Stéphane also has a strong track record of success in developing companies, both through internal and external growth. This expertise will be very useful to us in our next fundraising campaign, which is expected to begin in 2021“, said Sylvie Sauvaigo, President and Founder and CSO of LXRepair.